Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Target Lowered at JPMorgan Chase & Co.

Enanta Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan cut Enanta Pharmaceuticals’ price target from $19 to $17 but maintained its Overweight rating; the new target implies about 121% upside from the stock’s $7.68 price.
  • Analyst views are mixed: MarketBeat reports a consensus “Moderate Buy” rating and $19 average target, while two analysts rate the stock Sell.
  • Enanta’s latest quarterly results fell short of expectations, with a loss of $0.81 per share versus the $0.72 expected and revenue of $12.87 million versus $14.62 million forecast.
  • Five stocks we like better than Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) had its price objective cut by JPMorgan Chase & Co. from $19.00 to $17.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 121.35% from the stock's current price.

Several other equities research analysts have also weighed in on ENTA. Wall Street Zen lowered Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday, October 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Thursday, October 15th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $19.00.

Get Our Latest Stock Report on Enanta Pharmaceuticals

Enanta Pharmaceuticals Price Performance

Shares of ENTA traded down $0.30 during midday trading on Friday, reaching $7.68. The stock had a trading volume of 152,232 shares, compared to its average volume of 221,242. The company has a market cap of $223.64 million, a price-to-earnings ratio of -3.27 and a beta of 0.75. The company's fifty day simple moving average is $11.59 and its two-hundred day simple moving average is $13.00. Enanta Pharmaceuticals has a 1-year low of $7.63 and a 1-year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, November 16th. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.09). Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 64.32%. The business had revenue of $12.87 million during the quarter, compared to analysts' expectations of $14.62 million. On average, sell-side analysts forecast that Enanta Pharmaceuticals will post -2.24 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC increased its stake in Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company's stock valued at $47,717,000 after buying an additional 54,396 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at about $53,252,000. BlackRock Inc. acquired a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $47,304,000. ADAR1 Capital Management LLC purchased a new position in Enanta Pharmaceuticals during the second quarter worth about $19,603,000. Finally, Spruce Street Capital LP acquired a new stake in Enanta Pharmaceuticals in the second quarter valued at about $15,873,698. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta's work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company's history of applying its drug-discovery expertise to antiviral therapies.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enanta Pharmaceuticals Right Now?

Before you consider Enanta Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.

While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines